Table 1.
Transplantation demographics
| Variable | |
|---|---|
| Number of patients | 781 |
| Number of centers | 98 |
| Male patient gender | 401 (51) |
| Patient age, median (range), years | 50 (18–78) |
| 18–20 years | 28 (4) |
| 21–30 years | 91 (12) |
| 31–40 years | 105 (13) |
| 41–50 years | 174 (22) |
| 51–60 years | 248 (32) |
| >60 years | 135 (17) |
| Donor age, median (range), years | 31 (18–60) |
| Sex of donor/patient | |
| Female/male | 110 (14) |
| Other combinations | 669 (86) |
| Missing | 2 (<1) |
| Karnofsky prior to transplant ≥ 90 (only evaluable for 750 patients) | 500 (64) |
| CMV serostatus of donor/patient | |
| Negative/negative | 235 (30) |
| Other combinations | 529 (68) |
| Unknown | 17 (2) |
| HLA match (HLA-A, B, C, DRB1) | |
| 7/8 | 175 (22) |
| 8/8 | 606 (78) |
| Disease at transplant | |
| Acute myeloid leukemia | 624 (80) |
| Early | 439 (70) |
| Intermediate | 185 (30) |
| Myelodysplastic syndrome | 157 (20) |
| Early | 79 (50) |
| Advanced | 78 (50) |
| IPSS prior to transplant | |
| Low | 29 (18) |
| Intermediate 1 | 81 (52) |
| Intermediate 2 | 36 (23) |
| Unknown | 11 (7) |
| Graft Type | |
| Bone marrow | 136 (17) |
| Peripheral blood stem cells | 645 (83) |
| Conditioning regimen | |
| Myeloablative | 564 (72) |
| Busulphan based | 402 (71) |
| Total body irradiation based | 162 (29) |
| Reduced intensity | 217 (28) |
| Busulphan based | 126 (58) |
| Melphalan based | 41 (19) |
| Nonmyeloablative | 50 (23) |
| Graft-versus-host disease prophylaxis | |
| Calcinerin inhibitor + methotrexate ± other | 502 (64) |
| Calcinerin inhibitor ± other (no methotrexate) | 266 (34) |
| Other combinations | 13 (2) |
| Transplantation year | |
| 2008 | 159 (20) |
| 2009 | 361 (46) |
| 2010 | 261 (33) |
Values are number of cases with percents in parenthesis, unless otherwise specified.